Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus Prednisone in mCRPC
NCT00676650Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jul 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of sunitinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pfizer. Started Jul 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00676650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676650.